European Regulators Endorse Sanofi's Sleeping Sickness Drug
Analysis based on 10 articles · First reported Feb 27, 2026 · Last updated Feb 27, 2026
The endorsement of acoziborole by the European Union===European Medicines Agency is a positive development for the pharmaceutical sector, particularly for Sanofi, as it validates their research and development efforts. This could lead to increased market confidence in Sanofi's drug pipeline and potentially influence other companies to invest in treatments for neglected diseases.
European drug regulators, specifically the European Union===European Medicines Agency, have endorsed acoziborole, a new and simpler treatment for sleeping sickness developed by Sanofi. This decision is a critical step towards making the medicine available in countries like Democratic Republic of the Congo and Guinea, which have a high incidence of the disease. The new treatment, consisting of three pills taken as a one-time dose, offers a more accessible alternative to current arduous regimens, potentially accelerating the elimination of sleeping sickness. Sanofi has committed to donating doses to the World Health Organization, ensuring the drug will be free to patients. While researchers like Monica Mugnier acknowledge the improvement, they also note that challenges remain in fully eradicating the disease.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard